Back to results
US 2024/0199638 A1Published application
Glutarimides for medical treatment
AssigneeC4 Therapeutics, Inc.
InventorsRoger Norcross, Annick Goergler, Philipp Schmid, Fabian Dey, Eric Andre Kusznir
Life of this patent
Estimating the term…
Abstract
The present invention provides selected glutarimides which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
Claims15
A method for the treatment of cancer comprising administering an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof to a human patient,
- wherein
- R1 is selected from the group consisting of
- i) aryl, optionally substituted by one R3 substituent,
- ii) heterocycloalkyl, optionally substituted by one R4 substituent,
- iii) cycloalkyl, optionally substituted by one R5 substituent, and
- iv) heteroaryl, optionally substituted by one R6 substituent,
- R2 is H, C1-6alkyl or —NC(═O)—C1-4alkyl,
- R3 is H or C1-6alkyl,
- R4 is H or C1-6alkyl,
- R5 is H or C1-6alkyl,
- R6 is H, C1-6alkyl, —C(═O)O—C1-6alkyl or oxo,
- n is 0 or 1.
9 more elements
Dependencies are inferred from the claim text.